(1,2-dihydronaphthalen-4-yl)methanamine hydrochloride | 80096-46-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (1,2-dihydronaphthalen-4-yl)methanamine hydrochloride
• 英文别名: 3,4-Dihydronaphthalen-1-ylmethanamine;hydrochloride
• CAS: 80096-46-4
• 化学式: C₁₁H₁₃N*ClH
• 分子量: 195.692
• InChiKey: LCSFBEVCTLMZGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (1,2-dihydronaphthalen-4-yl)methanamine hydrochloride 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 反应 3.5h， 以60%的产率得到1,2,3,4-四氢-1-萘甲胺盐酸盐
  参考文献：
  名称：

  Cathinone及其相关类似物的血清素受体亲和力。

  摘要：

  使用分离的大鼠眼底制剂检查了一系列的卡西酮（α-氨基苯乙酮）类似物。（S）-（-）-Cathinone的血清素受体亲和力是（+/-）-Cathineone的两倍，外消旋苯丙胺的亲和力是其四倍。发现卡西酮的几种衍生物要么具有比母体化合物更低的亲和力，要么不以竞争方式与受体相互作用。几种新的类似物1-（氨基甲基）-3,4-二氢萘盐酸盐（3），4-（氨基甲基）-3-色烯盐酸盐（4b）及其6-甲氧基衍生物a与血清素受体相互作用，但以最有可能与取代的卡西酮类似物的相互作用不同的方式。

  DOI：

  10.1021/jm00346a012
• 作为产物：
  描述：

  1-氨基甲基-1,2,3,4-四氢-萘-1-醇 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 以72%的产率得到(1,2-dihydronaphthalen-4-yl)methanamine hydrochloride
  参考文献：
  名称：

  N6-Substituted adenosine receptor agonists: potential antihypertensive agents

  摘要：

  Adenosine is known to exert a wide range of pharmacological effects including hypotension. This effect of adenosine suggested that modified analogues of adenosine might provide useful antihypertensive agents. Thus, we prepared a series of novel N6-benzocycloalkyladenosines and studied their receptor binding and antihypertensive activity. The structure-activity relationship study shows that the adenosine analogues having the hydrophobic phenyl moiety one carbon away from the C6-nitrogen have modest affinity and selectivity for the A1 receptor, whereas those with the phenyl moiety two carbons away from the C6-nitrogen have excellent affinity and selectivity for the A1 receptor. Many of these analogues showed excellent antihypertensive activity with a wide range of effects on heart rate. There is no direct correlation between the receptor binding affinities and antihypertensive activity; however, it is more closely associated with A1 than A2 affinity. The bradycardic effect of these agonists seems to be due to the A1 affinity. From this set, compound 3 was further evaluated in secondary antihypertensive screens. It lowered the blood pressure dose dependently with effects lasting for over 20 h following administration of a 30 mg/kg dose. Compound 3 was also effective in lowering blood pressure in a renal hypertensive rat model. Thus, appropriately modified N6-substituted adenosines represent a novel class of antihypertensive agents.

  DOI：

  10.1021/jm00107a025

文献信息

• [EN] ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST<br/>[FR] FLUORATION ÉLECTROPHILE ASYMÉTRIQUE UTILISANT UN CATALYSEUR DE TRANSFERT DE PHASE CHIRAL ANIONIQUE
  申请人：UNIV CALIFORNIA

  公开号：WO2013096971A1

  公开（公告）日：2013-06-27

  The discovery of distinct modes of asymmetric catalysis has the potential to rapidly advance chemists' ability to build enantioenriched molecules. As an example, the use of chiral cation salts as phase-transfer catalysts for anionic reagents has enabled a vast set of enantioselective transformations. A largely overlooked analogous mechanism wherein a chiral anionic catalyst brings a cationic species into solution is itself a powerful method. The concept is broadly applicable to a number of different reaction pathways, including to the enantioselective fluorocyclization of olefins, and dearomatization of aromatic systems with a cationic electrophile-transferring (e.g., fluorinating) agent and a chiral phosphate catalyst. The reactions proceed in high yield and stereoselectivity. The compounds and methods of the invention are of particular value, especially considering the scarcity of alternative approaches.

  发现不对称催化的不同模式具有潜力快速推动化学家构建手性富集分子的能力。例如，使用手性阳离子盐作为相转移催化剂用于阴离子试剂已经实现了大量手性选择性转化。一个被大多数人忽视的类似机制是手性阴离子催化剂将阳离子物种溶解到溶液中，这本身就是一种强大的方法。这一概念广泛适用于许多不同的反应途径，包括对烯烃进行手性选择性氟环化和用阳离子亲电试剂转移（例如，氟化）剂和手性磷酸盐催化剂进行芳香系统去芳构化。这些反应产率高，立体选择性好。该发明的化合物和方法具有特殊价值，尤其考虑到替代方法的稀缺性。
• 一种盐酸帕洛诺司琼盐酸盐的合成工艺
  申请人：陕西开元制药有限公司

  公开号：CN107089979B

  公开（公告）日：2019-06-28

  本发明公开了一种盐酸帕洛诺司琼盐酸盐的合成工艺，包括如下步骤：步骤S1，以3,4‑二氢‑1‑萘甲胺盐酸盐和3‑奎宁环酮盐酸盐为原料缩合还原制备得到N‑[(3,4‑二氢萘‑1‑基)甲基]‑(S)‑1‑氮杂二环[2.2.2]辛烷‑3‑胺的正丁醇溶液；步骤S2，直接在N‑[(3,4‑二氢萘‑1‑基)甲基]‑(S)‑1‑氮杂二环[2.2.2]辛烷‑3‑胺的正丁醇溶液中加入催化剂氢化还原得到N‑[(1,2,3,4‑四氢萘‑1‑基)甲基]‑(S)‑1‑氮杂二环[2.2.2]辛烷‑3‑胺；步骤S3，将N‑[(1,2,3,4‑四氢萘‑1‑基)甲基]‑(S)‑1‑氮杂二环[2.2.2]辛烷‑3‑胺环合成盐得到盐酸帕洛诺司琼盐酸盐。本发明提供的合成工艺条件温和、步骤简单、收率高，优于现有技术。
• ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20140350253A1

  公开（公告）日：2014-11-27

  The discovery of distinct modes of asymmetric catalysis has the potential to rapidly advance chemists' ability to build enantioenriched molecules. As an example, the use of chiral cation salts as phase-transfer catalysts for anionic reagents has enabled a vast set of enantioselective transformations. A largely overlooked analogous mechanism wherein a chiral anionic catalyst brings a cationic species into solution is itself a powerful method. The concept is broadly applicable to a number of different reaction pathways, including to the enantioselective fluorocyclization of olefins, and dearomatization of aromatic systems with a cationic electrophile-transferring (e.g., fluorinating) agent and a chiral phosphate catalyst. The reactions proceed in high yield and stereoselectivity. The compounds and methods of the invention are of particular value, especially considering the scarcity of alternative approaches.

  不对称催化的不同模式的发现有潜力快速推进化学家构建对映富集分子的能力。例如，手性阳离子盐作为相转移催化剂用于阴离子试剂的使用已经实现了广泛的对映选择性转化。一个被大多数人忽视的类似机理是手性阴离子催化剂将阳离子物种溶解进溶液中的强大方法。这个概念广泛适用于许多不同的反应途径，包括烯烃的对映选择性氟杂环化和芳香体系的脱芳香化，使用离子型电子亲合试剂（例如氟化试剂）和手性磷酸盐催化剂。反应具有高产率和立体选择性。该发明的化合物和方法具有特殊价值，特别是考虑到替代方法的稀缺性。
• N6-substituted adenosines
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0179667A2

  公开（公告）日：1986-04-30

  There is disclosed a compound of the following general formula (I): its diastereomer, or a pharmaceutically acceptable acid addition salt thereof; wherein R1 is of the formula or in which; n is an integer of from one to four; Z is hydrogen, lower alkyl or hydroxy; Y is hydrogen, lower alkyl, or OR where R is hydrogen, lower alkyl or lower alkanoyl; A is a bond or a straight or branched alkylene of from one to four carbon atoms, with the proviso that A cannot be a bond when R1 is of Formula II and n is one; X and X' are each, independently, hydrogen, lower alkyl, lower alkoxy, hydroxy, lower alkanoyl, nitro, trifluoromethyl, halogen, amino, monolower-alkyl or diloweralkylamino, or when taken X and X' together are a methylenedioxy group; R2 is a) hydrogen, b) halogen, c) NR'R" where R' and R" are independently hydrogen, lower alkyl, phenyl, or phenyl substituted by lower alkyl, lower alkoxy, halogen, or trifluoromethyl, d) SR'" where R" is hydrogen, lower alkyl, lower alkanoyl, benzoyl, or phenyl; R'2, R'3 and R'e are each, independently, hydrogen, alkanoyl having two to twelve carbon atoms, inclusive, in a straight or branched alkyl chain, benzoyl, or benzoyl substituted by lower alkyl, lower alkoxy, halogen, or R'2 and R'3 taken together are a five- membered ring having a total of up to twenty carbons; or R'e is, independently, a phosphate, hydrogen, or dihydrogen phosphate, or an alkali metal or ammonium, or dialkali or diammonium salt thereof; with the proviso that overall when R1 is II and X' X', Y, and Z are hydrogen, or lower alkyl then n cannot be two. The novel N6-substituted adenosines have desirable ratio of affinities at A1 or A2 receptors and highly desirable central nervous system and cardiovascular activities, such as analgesic, antipsychotic, sedative, or antihypertensive as well as immunoinflammatory activity.

  本发明公开了一种通式（I）如下的化合物： 其非对映异构体，或其药学上可接受的酸 加成盐； 其中 R1 为式 或 其中 n 是 1 到 4 的整数； Z 是氢、低级烷基或羟基； Y 是氢、低级烷基或 OR，其中 R 是氢、低级烷基或低级烷酰基； A 是键或 1 至 4 个碳原子的直链或支链亚烷基，但当 R1 为式 II 且 n 为 1 时，A 不能为键； X和X'各自独立地为氢、低级烷基、低级烷氧基、羟基、低级烷酰基、硝基、三氟甲基、卤素、氨基、单低级烷基或稀低烷基氨基，或当X和X'合在一起时为亚甲基二氧基； R2 是 a) 氢，b) 卤素，c) NR'R"，其中 R' 和 R "独立地是氢、低级烷基、苯基或被低级烷基、低级烷氧基、卤素或三氟甲基取代的苯基，d) SR'"，其中 R" 是氢、低级烷基、低级烷酰基、苯甲酰基或苯基； R'2、R'3 和 R'e 各自独立地是氢、在直链或支链烷基中具有 2 至 12 个碳原子的烷酰基、苯甲酰基或被低级烷基、低级烷氧基、卤素取代的苯甲酰基，或 R'2 和 R'3 合在一起是一个总碳数不超过 20 个的五元环；或 R'e 独立地是磷酸、氢或磷酸二氢、或碱金属或铵、或二碱或二铵盐；但总体上，当 R1 是 II 且 X' X'、Y 和 Z 是氢、或低级烷基时，则 n 不能为 2。 新型 N6 取代腺苷在 A1 或 A2 受体上具有理想的亲和力比率，并具有非常理想的中枢神经系统和心血管活性，如镇痛、抗精神病、镇静或抗高血压以及免疫炎症活性。
• Transition Metal-Free Trifluoromethylation of<i>N</i>-Allylamides with Sodium Trifluoromethanesulfinate: Synthesis of Trifluoromethyl-Containing Oxazolines
  作者：Jipan Yu、Haijun Yang、Hua Fu

  DOI：10.1002/adsc.201400144

  日期：2014.11.24

  AbstractA transition metal‐free method for the trifluoromethylation of N‐allylamides has been developed, and the corresponding trifluoromethyl‐containing oxazolines were prepared in moderate to good yields. The protocol uses readily available substituted N‐allylamides as the starting materials, inexpensive and easily stored sodium trifluoromethanesulfinate as the trifluoromethyl source, iodobenzene diacetate as the oxidant, and the procedure involves sequential intermolecular trifluoromethylation of alkenes with sodium trifluoromethanesulfinate and intramolecular cyclization. This is the first example to prepare CF3‐containing oxazolines. Therefore, the present method should afford an efficient and practical strategy for synthesis of other CF3‐containing cyclic compounds.magnified image